상세정보
Export to Refworks부가기능
Therapeutic development in the absence of predictive animal models of nervous system disorders : proceedings of a workshop
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | Therapeutic development in the absence of predictive animal models of nervous system disorders : proceedings of a workshop/ Lisa Bain, Sheena M. Posey Norris, Noam I. Keren, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.. |
| 개인저자 | Bain, Lisa J.,rapporteur. Stroud, Clare,rapporteur, Keren, Noam I.,rapporteur, Norris, Sheena M. Posey,rapporteur, |
| 단체저자명 | National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders,issuing body. |
| 발행사항 | Washington, DC: the National Academies Press, [2017]. |
| 형태사항 | 1 online resource (xii, 82 pages): illustrations. |
| 기타형태 저록 | Print version: National Academies of Sciences, Engineering, and Medicine Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders : Proceedings of a Workshop Washington, D.C. : National Academies Press,c1969 9780309455138 |
| ISBN | 9780309455145 0309455146 |
| 일반주기 |
"A report of the National Academies of Sciences, Engineering, Medicine."
|
| 서지주기 | Includes bibliographical references (pages 61-65). |
| 내용주기 | Introduction and overview -- Drug development for nervous system disorders: overview of challenges adn potential opportunities -- Case studies: therapeutic development for Parkinson's disease and schizophrenia in the absence of predictive animal models of disease -- New modeling approaches for nervous system disorders -- Private-sector thresholds for investment in neuroscience clinical trials -- Ethical considerations -- Regulatory perspectives -- Appendix A: References -- Appendix B: Workshop agenda -- Appendix C: Registered attendees. |
| 요약 | 'Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop"--Publisher's description. |
| 회의명 | Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders : a Workshop (2016 : Washington, D.C.) |
| 일반주제명 | Nervous system --Diseases --Congresses. MEDICAL / Pharmacology |
| 언어 | 영어 |
| 바로가기 |  |
